Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
Stock market expert Jon Erlichman recently shared a review of stock returns during the last six U.S. recessions, highlighting those that have performed well in difficult times.
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
Johnson & Johnson and Albertsons Companies' stock have provided a pleasant hedge against market volatility, with the S&P 500 and Nasdaq remaining near correction territory.
Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a Fireside Chat at 1:35 p.m. Eastern Time.
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.
Johnson & Johnson (JNJ) reported upbeat Q1 results amid an exciting earnings season, with analysts noting impressive sales and guidance from the pharma giant.
Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios
Edgewell and Kenvue are under-the-radar consumer staples stocks poised to gain as the U.S. dollar declines. Learn why they may boost your income portfolio.
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.9% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases.
Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.”
